These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19162218)

  • 21. Editorial: Strategies in the drug discovery and development for leishmaniasis: immunomodulators, natural products, synthetic compounds, and drug repositioning.
    de Almeida TF; Cunha-Junior EF; Wanderley JLM; Pacheco JDS; Pinto-da-Silva LH; Andrade-Neto VV; Chaves SP
    Front Cell Infect Microbiol; 2024; 14():1384244. PubMed ID: 38544526
    [No Abstract]   [Full Text] [Related]  

  • 22. Emerging peptide therapeutics for inflammatory autoimmune diseases.
    Briand JP; Muller S
    Curr Pharm Des; 2010; 16(9):1136-42. PubMed ID: 20030611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding autoimmune disease: new targets for drug discovery.
    Balagué C; Kunkel SL; Godessart N
    Drug Discov Today; 2009 Oct; 14(19-20):926-34. PubMed ID: 19596080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoimmune consequences of biologics.
    Dhital R; Kavanaugh A
    J Allergy Clin Immunol; 2022 Jan; 149(1):48-50. PubMed ID: 34838586
    [No Abstract]   [Full Text] [Related]  

  • 25. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The immunoproteasome: a novel drug target for autoimmune diseases.
    Basler M; Mundt S; Bitzer A; Schmidt C; Groettrup M
    Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S74-9. PubMed ID: 26458097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment.
    Murphy G; Lisnevskaia L; Isenberg D
    Lancet; 2013 Aug; 382(9894):809-18. PubMed ID: 23972423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of Combination High-Throughput Phenotypic Screening and Target Identification Methods for the Discovery of Natural Product-Based Combination Drugs.
    Isgut M; Rao M; Yang C; Subrahmanyam V; Rida PCG; Aneja R
    Med Res Rev; 2018 Mar; 38(2):504-524. PubMed ID: 28510271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologics: a new approach needed?
    Foster KA
    Drug Discov Today; 2010 Feb; 15(3-4):81-3. PubMed ID: 19778630
    [No Abstract]   [Full Text] [Related]  

  • 30. [Immune-pharmacology study on the immunoregulatory effects of Dabuyin Wan in autoimmune mice induced by Campylobacter jejuni].
    Wang Y; Zhao Y
    Zhong Yao Cai; 2007 May; 30(5):567-70. PubMed ID: 17727064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pediatric psoriasis: updates in biologic therapies.
    Sukhatme SV; Gottlieb AB
    Dermatol Ther; 2009; 22(1):34-9. PubMed ID: 19222515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Updates in the field of autoimmune pancreatitis: a clinical guide.
    de Pretis N; Amodio A; Frulloni L
    Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):705-709. PubMed ID: 29923430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety assessment of immunomodulatory biologics: the promise and challenges of regulatory T-cell modulation.
    Ponce RA
    J Immunotoxicol; 2011; 8(4):389-97. PubMed ID: 21913866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic Therapies for Rheumatologic and Autoimmune Conditions.
    Bays AM; Gardner G
    Med Clin North Am; 2016 Jul; 100(4):719-31. PubMed ID: 27235612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell factor 1: A master regulator of the T cell response in disease.
    Escobar G; Mangani D; Anderson AC
    Sci Immunol; 2020 Nov; 5(53):. PubMed ID: 33158974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T cell immunomodulation--the Holy Grail of therapeutic tolerance.
    Isaacs JD
    Curr Opin Pharmacol; 2007 Aug; 7(4):418-25. PubMed ID: 17611158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic tolerance in autoimmune disease.
    Rayner F; Isaacs JD
    Semin Arthritis Rheum; 2018 Dec; 48(3):558-562. PubMed ID: 30348449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry).
    Pérez-De-Lis M; Retamozo S; Flores-Chávez A; Kostov B; Perez-Alvarez R; Brito-Zerón P; Ramos-Casals M
    Expert Opin Drug Saf; 2017 Nov; 16(11):1255-1271. PubMed ID: 28854831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of immunological tolerance using monoclonal antibodies: applications to organ transplantation and autoimmune disease.
    Bach JF
    C R Biol; 2006 Apr; 329(4):260-2. PubMed ID: 16644496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases.
    Ulivieri C; Baldari CT
    Pharmacol Res; 2014 Oct; 88():41-52. PubMed ID: 24657239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.